News

Appointment of GM - Global Sales & Marketing

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that Mr. Ajay Nair has been appointed to the new role of General Manager - Global Sales & Marketing.

Read more

Resonance Health News - June 2021

Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities.

To read the newsletter please click here

Appointment of Chief Financial Officer & Company Secretary

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021. 

Read more

HepaFat-AI Receives CE Marking

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).

Read more

HepaFat-AI Receives TGA Approval

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received Australian Therapeutic Goods Administration (“TGA”) approval for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).

Read more

HepaFat-AI gains US FDA clearance

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) announces that it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) for HepaFat-AI, a medical device (software) that is fully automated and uses artificial intelligence (“AI”) to assess liver fat.

Read more